Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $131 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...

You might think you're done with the multiverse, but the multiverse is not done with you in Apple TV's new season of its ...